Liquidia Corp
Liquidia Corporation (Nasdaq: LQDA) is a biopharmaceutical company developing and commercializing treatments for respiratory and vascular diseases, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its commercial products are YUTREPIA, an… From the company’s description.
Over the twelve months to Jun 30, 2026, Liquidia Corp reported revenue of $450.91M, up 2233.6% from a year earlier, and net income of $138.61M. Its operating margin was 37.4%, and operations generated $167.71M in cash. In fiscal 2025, it reported revenue of $158.32M, up 1031.2% from fiscal 2024, and a net loss of $68.92M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Liquidia Corp does
In the company’s own words
Liquidia Corporation (Nasdaq: LQDA) is a biopharmaceutical company developing and commercializing treatments for respiratory and vascular diseases, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its commercial products are YUTREPIA, an inhaled dry-powder treprostinil approved for PAH and PH-ILD, and generic treprostinil injection, which it promotes in the United States with Sandoz and for which it shares profits. Liquidia also develops L606, an investigational sustained-release inhaled treprostinil formulation, and uses its PRINT particle-engineering technology to produce uniform drug particles. The company operates through its wholly owned subsidiaries Liquidia Technologies and Liquidia PAH, and has a targeted U.S. commercial field force serving healthcare providers and stakeholders involved in treatment, distribution and reimbursement. YUTREPIA began commercialization in June 2025; the company’s 45,000-square-foot facility in Morrisville, North Carolina, supports particle design, formulation and manufacturing. Its website is www.liquidia.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MORRISVILLE, NC
- Fiscal year end
- December
- CIK
- 1819576
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Liquidia Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Liquidia Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Liquidia Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Liquidia Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Liquidia Corp's last four quarterly filings that the numbers alone won't show?”